SCHEMBL22894151

SCHEMBL22894151

Cc1ccc(OCCc2ccc(F)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.62
DRD4 P21917 3/20 0.62
DRD3 P35462 3/20 0.62
KCNH2 Q12809 1/20 0.57
MAOB P27338 3/20 0.50
NPC1 O15118 1/20 0.50
ACHE P22303 1/20 0.50
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
MAOA P21397 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15079877 1.00 DRD2 (0.62) DRD2DRD4DRD3KCNH2MAOB
Hydrochloric Acid SCHEMBL27900803 0.98 DRD2 (0.60) DRD2DRD4DRD3KCNH2MAOB
SCHEMBL14173881 0.92 KCNH2 (0.65) DRD2DRD4DRD3KCNH2MAOB
Hydrochloric Acid SCHEMBL27900832 0.90 KCNH2 (0.62) DRD2DRD4DRD3KCNH2MAOB
SCHEMBL15079869 0.90 MAOB (0.58) MAOBNPC1MAOAL3MBTL1CYP1A2
SCHEMBL8053251 0.88 DRD2 (0.70) DRD2DRD4DRD3NPC1ACHE
SCHEMBL22894194 0.85 KMT2A (0.60) DRD2DRD4DRD3KCNH2MAOB
SCHEMBL19012412 0.85 KMT2A (0.60) DRD2DRD4DRD3KCNH2MAOB
SCHEMBL14586644 0.83 DRD2 (0.60) DRD2DRD4DRD3KCNH2MAOB
SCHEMBL20750259 0.83 KCNH2 (0.56) DRD2DRD4DRD3KCNH2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2023-07-11 US disclosed
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2023-07-11 US disclosed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US disclosed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof VIP, CUTA, MGAM DRD2 3905/4885DRD4 3720/4885DRD3 3753/4885
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof VIP, CUTA, MGAM DRD2 3905/4885DRD4 3720/4885DRD3 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.